Researcher.Life Logo

Isidorianum : Impact Factor & More

eISSN: 2660-7743pISSN: 1131-7027
JournalOpen Access
Recommended pre-submission checks
Powered by Paperpal by Editage

Isidorianum Journal Specifications

Indexed in the following public directories

  • DOAJ DOAJ
Overview
Publisher Facultad de Teología San Isidoro de Sevilla
Language English,French,German,Italian,Portuguese,Spanish
Publication Time12
Editorial Review ProcessPeer review
General Details
LanguageEnglish,French,German,Italian,Portuguese,Spanish
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 12
Editorial Review Detail
Editorial TeamVisit website
Review ProcessPeer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC-ND
OA statementVisit website
View less

Planning to publish in Isidorianum ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Isidorianum

Germline Pathogenic Variants in Breast Cancer-Predisposing Genes Among Early-Onset Female and Male Breast Cancer in Ethiopia.
  • 1 May 2026
  • JCO global oncology
Prevalence and Factors Associated With Financial Toxicity Among Patients With GI Cancer in Pakistan.
  • 1 May 2026
  • JCO global oncology
Blind Spots in Oncology Guidelines: Evidence and Practice in India and Low- and Middle-Income Country Parallels.
  • 1 May 2026
  • JCO global oncology
Erratum: Evolution of Therapy in Pediatric ALL From Aminopterin to Chimeric Antigen Receptor T-Cell Therapy: Global Advances, Indian Adaptations, and Lessons for Low- and Middle-Income Countries.
  • 1 May 2026
  • JCO global oncology
Outcomes of Hypofractionated Radiotherapy in Patients With Geriatric Head and Neck Cancer: Role of Comprehensive Geriatric Assessment.
  • 1 May 2026
  • JCO global oncology
Improving Chimeric Antigen Receptor T Access in Latin America: Promises, Barriers, and a Call to Action.
  • 1 Apr 2026
  • JCO global oncology
Germline Pathogenic Variants in Breast Cancer-Predisposing Genes Among Early-Onset Female and Male Breast Cancer in Ethiopia.
  • 1 May 2026
  • JCO global oncology
Prevalence and Factors Associated With Financial Toxicity Among Patients With GI Cancer in Pakistan.
  • 1 May 2026
  • JCO global oncology
Blind Spots in Oncology Guidelines: Evidence and Practice in India and Low- and Middle-Income Country Parallels.
  • 1 May 2026
  • JCO global oncology
Erratum: Evolution of Therapy in Pediatric ALL From Aminopterin to Chimeric Antigen Receptor T-Cell Therapy: Global Advances, Indian Adaptations, and Lessons for Low- and Middle-Income Countries.
  • 1 May 2026
  • JCO global oncology
Outcomes of Hypofractionated Radiotherapy in Patients With Geriatric Head and Neck Cancer: Role of Comprehensive Geriatric Assessment.
  • 1 May 2026
  • JCO global oncology
Improving Chimeric Antigen Receptor T Access in Latin America: Promises, Barriers, and a Call to Action.
  • 1 Apr 2026
  • JCO global oncology

FAQs on Isidorianum